Joshua Rosenblat

Dr. Joshua Rosenblat, a clinician-researcher at the University of Toronto, discusses the groundbreaking role of ketamine and its derivative, esketamine, in treating treatment-resistant mood disorders. He highlights their quick effectiveness compared to traditional antidepressants and reviews the historical journey of ketamine's usage. Exploring barriers to accessibility in psychiatric care, he advocates for innovative solutions, while also addressing safety and efficacy across different age groups. It's a deep dive into transformative therapies that could reshape mental health treatment.